Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
WALTHAM, Mass., Nov. 21, 2016 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Morrison, M.D., will present at the 28th Annual Piper Jaffray Healthcare Conference on November 30, 2016 at 9:50 am EST at the Lotte New York Palace Hotel.
A live webcast of the Company’s presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to potentially enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers. For more information on Syndax, please visit www.syndax.com.
Investor Contacts Heather Savelle Argot Partners [email protected] Tel 646.395.3734 Media Contact Eliza Schleifstein Argot Partners [email protected] Tel 973.361.1546
